ABSTRACT
INTRODUCTION 41
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB), one of the 42 world's major health problems. Current vaccines and chemotherapeutic measures are limited in 43 their efficacy and are failing to prevent spread of the disease. The emergence of Mtb strains 44 resistant to the few front line drugs that are currently available makes it very difficult, too often 45 impossible, to cure fatal infections. Cationic antimicrobial peptides (CAMPs) produced by the 46 immune system can help resist infection. Since many CAMPs have rapid bactericidal activity 47 against a broad range of microbes and there is a low probability of pathogens acquiring 48 resistance (1), they represent promising new avenues for antibacterial drug development, 49 especially for multidrug resistant strains (2, 3) . 50
Thousands of CAMPs have evolved within bacteria, plants, and animals (2, 4). Indeed, 51 many antimicrobial peptides are under clinical development for treating a wide variety of 52 diseases (cited in 2). While a single mechanism does not underlie all effects of CAMPs, their 53 bactericidal activities often depend on their abilities to permeabilize membranes by creating 54 pores or disrupting the organization of the lipid bilayer. Partial depolarization of the cytoplasmic 55 membrane by CAMPs interferes with electron transport and oxidative metabolism, leading to cell 56 death (5, 6) . CAMP binding to ATP may mediate additional effects on metabolism (7-10). Directly 57 or indirectly, exposure to CAMPs reduces the activities of essential processes including synthesis 58 4 specific CAMPs and then bind, degrade, or extrude them from the membrane (1). Membrane 64 transporters also serve to extrude CAMPs from the cytoplasmic or inner membrane 65 compartments (14-16). The proliferation of intracellular pathogens within host cells is often 66 dependent on their abilities to sense and activate these resistance systems (17) . 67
Our understanding of the amino acid sequence requirements that underlie the 68 antimicrobial activities of CAMPs have been accelerated by the development of high throughput 69 assays and methods to analyze their physiochemical characteristics (18) (19) (20) . Physiochemical 70 characteristics of amino acids have been defined by dozens of quantitative structure-activity 71 relationships (QSARs), including various descriptors of hydrophobicity, hydrophilicity, 72 isoelectric point, charge, mass, volume, and other physiochemical characteristics (21). Although 73 none of the individual descriptors were predictive of activity, QSAR analyses showed that 74 antimicrobial activity was determined, to various extents, by combinations of these basic features 75 (21-24). These analyses identified common features of CAMPs that make them active against a 76 broad range of microbes and provided initial indications of specificity. In fact, several studies 77 have shown that peptides can have different activities against representative pathogenic bacteria 78 (21, 22, 25) , however this has never been statistically analyzed for possible correlations of their 79 activities against different organisms or with their physiochemical properties. The possible 80 activities of synthetic CAMPs against Mycobacterium species have not been reported. 81
The intrinsic drug resistance of Mtb, along with its slow growth rate and requirements for 82 biocontainment, have discouraged efforts to develop artificial small CAMPs effective against 83
Mtb. Mtb is often described as being CAMP tolerant. In fact, many natural CAMPs are only 84 active against Mtb at rather high concentrations that are not practical for TB treatment (26) (27) (28) (29) (30) (31) . 85
Furthermore, CAMPs can be cytotoxic to mammalian cells and long peptides are relatively 86 generate peptide library PL-D. PL-D was synthesized using standard Fmoc Chemistry on resin, 137 and HPLC purified to >85% purity afterwards. Peptides were weighed to obtain the final stock 138 concentration, but concentration was corrected based on the measured absorption of the peptides 139 at 280 nm, calculated using the amino acids W, F, C and Y. 140
141
Antimicrobial peptide activity assays. (i) The mycobacterial screen was performed in a final 142 volume of 100 µL 7H9* in sterile 96-well, round-bottom polypropylene microtiter plates 143 (Costar). Cell viability was assessed using the resazurin assay as previously described (32, 37) . 144
Briefly, Msmeg and Mtb cells were incubated in the presence of peptides for 3 or 8 days, and 145 then in the presence of resazurin for 1 or 2 days, respectively. A change from blue to pink 146 indicated bacterial growth. (ii) The activities of PL-D peptides against Mtb were determined 147 using a luciferase-based assay (luminescence) (32). Cultures were transferred from incubation 148 polypropylene microtiter plates to detection polystyrene plates (Costar ® ) and an equal volume of 149 Bright Glo Luciferase Assay Reagent (Promega) was then added to the plates. After a 15 minute 150 incubation, luminescence was measured in a Perkin Elmer Tropix luminometer using a 1-second 151 exposure. MIC 90 was calculated as the drug concentration that reduced luminescence by at least 152 90%, compared to untreated samples. Isoniazid (a benchmark anti-TB standard) was used for 153 calibration assays in 7H9* medium. Various conditions for luminescence detection were 154 optimized: the best signal with the highest dynamic range between growth and no growth 155 conditions was obtained after 72 hours incubation with 10 5 cells/mL inoculum and 100 µL 156 volume per well. Under these conditions, the MIC of isoniazid for Mtb-lux in 7H9* medium waspeptides. Peptides were introduced to Mtb-lux cultures in a 2-fold serial dilution format. As 160 internal controls, isoniazid and drug-free wells were also included in every peptide assay plate. 161 MIC values were the mean of two independent biological determinations. (iii) To measure 162 antimicrobial activity of the PL-D peptides against other microbial pathogens, 2-fold serial 163 dilutions of the peptides were introduced to cultures growing exponentially (2-7x10 5 cells/mL) in 164 polypropylene 96-well plates. After 18 hours incubation at 37ºC, the MIC was reported for the 165 lowest concentration of peptide were no growth was observed (39). PL-D activity against Msmeg 166 was determined by the resazurin assay. were quantified using a Mtb:lux strain (Table 1) p=0.0001) and decreased proportions of valine (V, p=0.0004). In other microbes, differences in 302 tryptophan or valine composition were not obvious (Supplemental Figure 1) and could not be 303 statistically evaluated due to the low numbers of negative peptides (Supplemental Table 1 ). These 304 remarkable differences in the activities of peptides against Msmeg compared to Mtb are likely due to 305 differences in their intrinsic resistance systems. 306
Determination of peptide cytotoxicity against human THP-1 cells. CAMP cytotoxicity to 307 human cells is also a significant concern for their development as clinical antibacterial agents (42). 308
Initial cytotoxicity studies were carried out using THP-1 (40), a human cell line that can be induced 309 to a macrophage-like state. Differentiated THP-1 cells are widely used in tuberculosis research and 310 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from for compound toxicity testing (43). The cytotoxicity of peptides was measured using differentiated 311 THP-1 cells and resazurin as an indicator of their viability. Many peptides in PL-D did not 312 generate significant toxicity using this assay. Results were expressed as selectivity indices, i.e., the 313 ratio of in vitro activity against Mtb relative to THP-1 toxicity (either 50% or 90% inhibition, SI 50 or 314 SI 90 ). SI 50 ranged from 3-256 with an average of 79 and SI 90 ranged from 1-51 with an average of 17 315 (Supplemental Table 2 In Mtb, envelope structure and self-defense systems provide resistance to the majority of 320 commonly used antibiotics as well as CAMPs (44). These intrinsic resistance systems were 321 believed to restrict the use of CAMPs in treating TB (31). However, after screening libraries of 322 peptides selected for activities against Paer, we were surprised to find that at least 30% had 323 significant activities against Mtb, including 26 with very low MIC values (1-10 µM). 324
Furthermore, screens of Paer-active peptides against diverse microbes showed that they had a 325 broad spectrum of antimicrobial activity associated with their positive charge (Term 1) and 326 hydrophobicity (Term 3; Figure 3) . However, our studies revealed that microbes each had their 327 own characteristic levels of sensitivity to CAMPs in our libraries. The median MICs of peptides 328 (PL-A) against individual pathogens varied about 10 fold (Table 1) ; some microbes, including 329
Mtb and Paer, had significantly higher average levels of CAMP resistance. Furthermore, 330 individual peptides had their own spectra of maximal activity against certain microbes or groups 331 of microbes. We were somewhat surprised to find that these individual activity spectra were not 332 simple reflections of microbial taxonomy. For example, activities against C. albicans (a fungus) 333 and various bacteria correlated better than most interbacterial pair comparisons. These 334 observations led us to hypothesize that the activities of CAMPs were determined largely by 335 commonly occurring genetic variations that provide resistance rather than stable genomic 336 elements that define bacterial taxa. This model is further supported by analyses of CAMP 337 activities in Mycobacterium species. Table 3 ) 364 and had an average length of 10 amino acids. Peptides that were most active against Mtb had 365 further increased proportions of tryptophan, which was offset by decreased proportions of some 366 uncharged amino acids (valine, alanine, isoleucine, and leucine). The fact that these differences 367 in amino acid composition were not observed in the same analyses of peptides more active 368 against other organisms, supports PCA analyses indicating unique features determine a degree of 369 specificity against Mtb. Furthermore, many of these peptides had low levels of toxicity against 370 macrophage-like human THP-1 cells. Additional cytotoxicity studies using multiple cell lines 371 will be needed to select the best candidates for in vivo testing. 372
Our studies showed that the activities of these peptides had significant specificity for Mtb, 373 and that this was associated with specific amino acid compositions. Together, these insights will be 374 used to improve peptide sequence design to increase their activities and specificity against Mtb, 375 including drug resistant strains, while minimizing cytotoxicity. In the future, better understandings of 376 the modes of action, resistance mechanisms, and pharmacological properties of CAMPs are needed 377 to accelerate their development as anti-infective therapies. (Table 2a) ,
and Msmeg (Table 2b) in the PL-A peptide library (See Methods section for definitions of "positive" or "negative" activity.). 
